A5000142286- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Cardiac Imaging and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Advanced MRI Techniques and Applications
- Bone health and treatments
- Prostate Cancer Diagnosis and Treatment
- Radiation Detection and Scintillator Technologies
- Peptidase Inhibition and Analysis
- Medical Imaging and Pathology Studies
- Nuclear Physics and Applications
- Neurological disorders and treatments
- Cardiac pacing and defibrillation studies
- Management of metastatic bone disease
- Radiation Dose and Imaging
- Advanced Radiotherapy Techniques
- Multiple Myeloma Research and Treatments
- Parkinson's Disease Mechanisms and Treatments
- Glioma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Cardiovascular Function and Risk Factors
- Thyroid Cancer Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Cancer Immunotherapy and Biomarkers
Sapienza University of Rome
2016-2025
Policlinico Umberto I
2017-2025
Morpho (United States)
2020
Biocompatible gold nanoparticles (AuNPs) are particularly interesting for photo-thermal therapy (PTT) of cancer treatment because their ability to convert light into heating efficiently. Nevertheless, the random accumulation AuNPs in tissues, mainly determined by retention time bloodstream, is one main limiting factors use PTT applications. For this reason, efficient targeting and monitoring selected tissues paramount importance. This manuscript reports on a new generation 99mTc-labeled...
Abstract Purpose To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([ 223 Ra]RaCl 2 ). Patients methods Baseline neutrophil-to-lymphocyte ratio (NLR), derived NLR (donor), lymphocyte-to-monocyte (LMR), platelet-to-lymphocyte (PLR), systemic inflammation index (SII), Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason (GS) group, number of...
Purpose Coronary artery disease (CAD) underestimation represents a major pitfall of single-photon emission computed tomography-myocardial perfusion imaging (SPECT-MPI). calcium score (CACS) has emerged as sensitive tool for the assessment suspect CAD; however, integration SPECT-MPI with CACS been seldom evaluated, so far, and was therefore aim present study. Methods Patients undergoing subsequent coronary angiography were included. ROC curves used to identify values best predictive CAD. In...
Background/Objectives: The prognostic value of baseline clinical parameters in predicting the survival prolonging effect Radium-223-dichloride (223RaCl2) for metastatic castration resistant prostate cancer (mCRPC) patients has been object intensive research and remains an open issue. This national multicenter study aimed to corroborate evidence ten years experience with 223RaCl2 by collecting data from eight Italian Nuclear Medicine Units. Methods: Data 581 consecutive mCRPC treated were...
Background/Objectives: Hereditary transthyretin-mediated amyloidosis (ATTRv) is a rare disease characterized by the deposition of amyloid in heart and peripheral nerves, particularly affecting small fibers. This study aims to evaluate autonomic cardiac involvement ATTRv. Methods: Twelve patients with ATTRv twelve sex- age-matched healthy subjects underwent 123I-mIBG scintigraphy early late heart-to-mediastinum ratio (eH/M lH/M), 99mTc-HDP bone scan scintigraphy, neurophysiological...
To investigate the effects of radical radiotherapy (RT) relevant interruptions (RRI), single (sRRI) or multiple (mRRI), on Biochemical Failure-Free Survival (BFFS), Metastases-Free (MFS) and Overall (OS) in prostate cancer (PCa) patients. We conducted a retrospective analysis involving 383 patients diagnosed with who received RT between March 2013 April 2021, doses ranging from 60 to 80 Gy (median dose 76.0 Gy), either alone combination androgen deprivation therapy. The study aimed evaluate...
Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) bone metastases (ALSYMPCA trial). Our aim was to assess clinical biochemical factors related survival, safety outcomes of a practice setting. We retrospectively analysed 32 mCRPC treated Radium-223, assessing scan, pain reduction, alkaline phosphatase (ALP) prostate-specific antigen (PSA) response (≥30% reduction). At...